Ispayeva Z 1
1. Clinical phenotypes and biomarkers in chronic urticaria
2. Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria: A Cross-Sectional Study from Kazakhstan
3. GENETIC ASSOCIATIONS WITH ASTHMA IN THE KAZAKH POPULATION: A CASE-CONTROL STUDY FOCUSING ON ACTN3 AND TSBP1 POLYMORPHISMS
4. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
5. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
6. Management of anaphylaxis due to COVID-19 vaccines in the elderly
7. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
8. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report
9. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
10. RELIABILITY AND VALIDITY OF THE KAZAKH-LANGUAGE ACT QUESTIONNAIRE AS AN ASTHMA CONTROL TOOL
11. Study of Kazakhstan inpatient childhood asthma: assessment of prevalence and factors influencing treatment adherence
12. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
13. Assessment of the quality of life in patients with atopic dermatitis using the Kazakh version of the questionnaire Dermatology Life Quality Index
14. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model
15. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data
16. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference
17. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study
1